"Axitinib affects cell viability and migration of a primary foetal lung adenocarcinoma culture"

Cancer Investigation

Volumn 32, Issue 1, 2014, Pages 13-21

  Menna, Cecilia ^a   De Falco, Elena ^b   Pacini, Luca ^b   Scafetta, Gaia ^b   Ruggieri, Paola ^b   Puca, Rosa ^b   Petrozza, Vincenzo ^b   Ciccone, Anna Maria ^b   Rendina, Erino Angelo ^b   Calogero, Antonella ^b   Ibrahim, Mohsen ^b  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antineoplastic drugs; Axitinib; Cancer primary cell cultures; Fetal lung adenocarcinoma; Lung adenocarcinoma; Vascular endothelial growth factor

Indexed keywords

AXITINIB; BEVACIZUMAB; CISPLATIN; ERLOTINIB; GEFITINIB; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; VASCULOTROPIN 165;

ARTICLE; CARCINOMA CELL; CELL MIGRATION; CELL VIABILITY; CHEMOSENSITIVITY; CLONOGENIC ASSAY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG RESPONSE; FETAL LUNG ADENOCARCINOMA; FETUS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; UPREGULATION;

EID: 84891525458     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357907.2013.861472     Document Type: Article

References (34)

1. El Ouazzani H, Jniene A, Bouchikh M, Achachi L, El Ftouh M, Achir A, El Fassy Fihry MT. Well-differentiated fetal adenocarcinoma: a very uncommon malignant lung tumor. Rev Port Pneumol 2012;18:39-41.
2. Aleong JC, Calaminici M, Sheaff M. The cytology of pulmonary well-differentiated foetal adenocarcinoma. Cytopathology 2006;17:155-156.
3. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N,Thunnissen E, Tsao M, Yankelewitz D. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of LungAdenocarcinoma. JThorac Oncol 2011;6:244-285.
4. Nakatani Y, Miyagi Y, Takemura T, Oka T, Yokoi T, Takagi M, Yokoyama S, Kashima K, Hara K, Yamada T, Nozawa A, Inayama Y, SakamotoK,OgawaN, KitamuraH, ReslM, Cho SH, KossMN, Mark EJ. Aberrant nuclear/cytoplasmic localization and genemutation of beta-catenin in classic pulmonary blastoma: beta-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastomatoid variant of carcinosarcoma. Am J Surg Pathol 2004;28:921-927.
5. Nakatani Y, Kitamura H, Inayama Y, Kamijo S, Nagashima Y, Shimoyama K, Nakamura N, Sano J, Ogawa N, Shibagaki T, Resl M, Mark EJ. Pulmonary adenocarcinomas of the fetal lung type: a clinicopathologic study indicating differences in histology, epidemiology, and natural history of low-grade and high-grade forms. Am J Surg Pathol 1998;22:399-411.
6. Liu Y, Xu ML, Zhong HH,Heng WJ,Wu BQ. EGFRmutations are more frequent in well-differentiated than in poor-differentiated lung adenocarcinoma. Pathol Oncol Res 2008;14:373-379.
7. Garib T, Chen G, Huang C Misek DE, Iannettoni MD, Hanash SM, Orringer MB, Beer DG. Genomic and proteomic analyses of vascular endothelial growth factor and insulin-like growth factorbinding protein 3 in lung adenocarcinomas. Clin Lung Cancer 2004;5:307-312.
8. Shijubo N, Su Uede T, Kon S, Maeda M, Segawa T, Imada A, Hirasawa M, Abe S. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 1999;160:1269-1273.
9. Roskoski R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol/Hematol 2007;62:179-213.
10. Kradin RL, Young RH, Dickersin GR, Dickersin GR, Kirkham SE, Mark EJ. Pulmonary blastoma with argyrophil cells and lacking sarcomatous features (pulmonary endodermal tumor resembling fetal lung). Am J Surg Pathol 1982;6:165-172.
11. Kodama T, Shimosato Y, Watanabe S, Koide T, Naruke T, Shimase J. Six cases of well-differentiated adenocarcinoma simulating fetal lung tubules in pseudoglandular stage. Comparison with pulmonary blastoma. Am J Surg Pathol 1984;8:735-744.
12. Amirat L, le Pimpec Barthes F, Danel C, Poulet B, Riquet M.Well differentiated fetal-type pulmonary adenocarcinoma: a tumour with a good prognosis. Rev Mal Respir 2003;20:429-432.
13. Fujino S, Asada Y, Konishi T, Asakura S, Kato H, Mori A. Well-differentiated fetal adenocarcinoma of lung. Lung Cancer 1995;13:311-316.
14. Ma PC. Personalized targeted therapy in advanced non-small cell lung cancer. Cleve Clin J Med 2012;79(1), eS56-eS60.
15. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, HendersonD, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011;6:244-285.
16. Labitzke R, Friedl P. A serum-free medium formulation supporting growth of humanumbilical cord vein endothelial cells in longterm cultivation. Cytotechnology 2001;35:87-92.
17. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nature Protocols 2006;1:2315-2319.
18. Chin TM, Quinlan MP, Singh A, Sequist LV, Lynch TJ, Haber DA, Sharma SV, Settleman J. Reduced erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment. Clin Cancer Res 2008;14:6867-6876.
19. Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K,Otani H, Kubo T, Jida M, Ueno T, AndoM, OginoA,Kiura K, Miyoshi S.The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. Lung Cancer 2012;75:161-166.
20. Noro R, Gemma A, Kosaihira S, Kokubo Y, Chen M, Seike M, Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A, Kudoh S. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. BMC Cancer 2006;6:277. doi:10.1186/1471-2407-6-277.
21. Cao YD, Huang PL, Sun XC, Ma J, Jin ZL, Cheng HY, Xu RZ, Li F, Qin SK, Deng YX, Ge XL. Silencing of high mobility group A1 enhances gemcitabine chemosensitivity of lung adenocarcinoma cells. Chin Med J (Engl) 2011;124:1061-1068.
22. Schicher N, Paulitschke V, Swoboda A, Kunstfeld R, Loewe R, Pilarski P, Pehamberger H, Hoeller C. Erlotinib and bevacizumab have synergistic activity against melanoma. Clin Cancer Res 2009;15:3495-3502.
23. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigueMA,Murray BW, Kania RS, O'Connor P, ShalinskyDR, Bender SL. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008;14:7272-7283.
24. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010;16:790-799.
25. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S,Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857-865.
26. De Falco E, Scafetta G, Napoletano C, Puca R, Vingolo EM, Ragona G, Iorio O, Frati G. A standardized laboratory and surgical method for in vitro culture isolation and expansion of human primary human Tenon's fibroblasts. Cell Tissue Bank 2013;14:277-287.
27. Scafetta G, Tricoli E, Siciliano C, Napoletano C, Puca R, Vingolo EM, Cavallaro G, Polistena A, Frati G, De Falco E. Suitability of human Tenon's fibroblasts as feeder cells for culturing human limbal epithelial stem cells. Stem Cell Rev Rep 2013. doi 10.1007/s12015-013-9451-6.
28. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010;16:790-799.
29. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S,Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857-865.
30. Pacinda SJ, Ledet SC, Gondo MM, Langston C, Brown RW, Carmona PA, Franklin RB, Roggli VL, Cagle PT. p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas. Hum Pathol 1996;27:542-546.
31. Hanahan D, Folkman J. Patterns and emergingmechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
32. Fukumura, D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 2007;74:72-84.
33. De Donatis A, Ranaldi F, Cirri P. Reciprocal control of cell proliferation and migration. Cell Commun Signal 2010;8:20. doi: 10.1186/1478-811X-8-20.
34. Martens UM. Small Molecules in Oncology. Recent Results in Cancer Research, Volume 184, PM Schlag and HJ Senn (eds.). Berlin: Springer, 2010, 33-42.